Tuesday September 23, 2014 0 comments
CENTENNIAL - Allosource, one of the nation's largest providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of cellular bone allografts, announced it signed a Space Act Agreement with NASA and the Jet Propulsion Laboratory (JPL) to collaborate on microbial research.
Allosource said it will leverage technologies developed by NASA/JPL for assembly and launch operations of various Mars missions to advance microbial research in tissue processing.
Manufacturer's Edge - formerly the Colorado Association for Manufacturing and Technology (CAMT) - and NASA are partners on a technology matching and product development assistance program to help Colorado companies use NASA resources to spur innovation for new products and processes.
"Working with NASA and JPL is an amazing achievement for Allosource, and we are grateful for Manufacturer's Edge's assistance in facilitating this relationship," said Thomas Cycyota, Allosource president and CEO.
"We are committed to researching and developing new processes that allow us to continue to maximize the gift of human tissue donation."
The molecular microbial detection technology used in the rigorous pre- and post-mission testing of Mars mission spacecraft components provides an opportunity for Allosource to evolve microbial testing on donated tissue, the company said.
NASA, JPL and Allosource will share ideas and processes related to microbiological testing methods and will look for new ways to rapidly detect the presence of microorganisms.
"This creative collaboration shows the value of connecting NASA's cutting-edge space program technology with Allosource's tissue testing methods to potentially impact countless lives," said Tom Bugnitz, Manufacturer's Edge CEO.